OVID
Ovid Therapeutics Inc

6,206
Mkt Cap
$336.28M
Volume
1,290.00
52W High
$2.72
52W Low
$0.2425
PE Ratio
-9.71
OVID Fundamentals
Price
$2.55
Prev Close
$2.62
Open
$2.56
50D MA
$1.73
Beta
1.09
Avg. Volume
1.15M
EPS (Annual)
-$0.2362
P/B
2.54
Rev/Employee
$315,304.35
$63.97
Loading...
Loading...
News
all
press releases
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold
Wall Street Zen raised shares of Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock
Wedbush lifted their target price on Ovid Therapeutics from $5.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·4d ago
News Placeholder
Ovid Therapeutics Q4 Earnings Call Highlights
Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct...
MarketBeat·6d ago
News Placeholder
Here's Why Ovid Therapeutics Stock Popped Higher Today
Key PointsOV329 may be safer and more potent than existing treatments...
Nasdaq News: Markets·6d ago
News Placeholder
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million funding boost extending runway into 2028.read more...
Benzinga·6d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Issues Quarterly Earnings Results, Beats Expectations By $0.16 EPS
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) released its earnings results on Tuesday. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of...
MarketBeat·6d ago
News Placeholder
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +158.71% and +195.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday
Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·21d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have earned a consensus recommendation of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·23d ago
<
1
2
...
>

Latest OVID News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.